AUROPHARMA / Q1-FY26 / claim-ledger

Audit the questions that mattered.

Aurobindo Pharma · Analyst questions, management answers, and the quality of the response where the ledger is available.

Research layer active

ConCallIQ research layer

Signal, with the source still visible.

Use the controls below to narrow the view, then follow the evidence into the next layer of context.

WatchQ1-FY26 · 2025-08-14Back to quarter ↗

Questions audited

Answered directly

58%

Numeric claims

Consistency

contradicted

Question ledger

What was answered, and how?

Damayanti Kerai · HSBC Securities

partial

Clarify if debt limit numbers are at EBITDA or revenue level.

You can take that as the top-line level. EBITDA, you can work it out yourselves.

Damayanti Kerai · HSBC Securities

direct

Can Aurobindo still make reasonable sales from generic Revlimid in FY26?

We have most of our generic Revlimid settlement quantities. We have sold it. We have nothing more to sell other than a minimal listing.

Damayanti Kerai · HSBC Securities

partial

Explain the API business decline and whether it is temporary.

API, the turnover has dropped mainly because of the pricing pressures. Otherwise, I think over a period of time, it will start recovering because it cannot sustain for a long time, right?

Damayanti Kerai · HSBC Securities

evasive

Key drivers for maintaining EBITDA guidance despite no Revlimid.

Yeah, because despite no generic Revlimid, we have been able to maintain them. The numbers of the last quarter are helping me to retain that confidence.

Tushar Manudhane · Motilal Oswal

partial

Operational losses for various plants in FY26 and outlook for FY27.

Last year, we have incurred losses predominantly, as you know, in PNG, QUL, and other things... we are expecting good EBITDA starting Q3 onwards. The losses will come down.

Tarang Agarwal · McKinsey & Co

direct

Is API pricing pressure from domestic supply or imports?

Because of both.

Tarang Agarwal · McKinsey & Co

declined

U.S. sales numbers for UGF in Q4 FY25 and Q1 FY26.

We are not giving that number separately, Tarang.

Tarang Agarwal · McKinsey & Co

partial

Free cash flow trend and whether $400-450 million annual is visible.

We will strive, we will endeavor to achieve a cash generation of $100 million quarter on quarter, subject to any strategic expenditures being incurred.

Surya Patra · PhillipCapital

direct

Nature of stocking impact in U.S. business – tariff-related?

What Subbu had alluded to was primarily, you know, the tariff is supposed to go in effect from April 1... some of the wholesalers have stocked up the product in anticipation.

Neha Manpuria · Bank of America

partial

Quantify destocking impact in U.S. oral solid business.

It's hard to quantify exactly the kind of amount... My guess would be it could be anywhere between half a month to one month.

Neha Manpuria · Bank of America

direct

Is injectable business back to pre-disruption levels?

We are back to pre-disruption levels with respect to injectable business. I'm very, very confident.

Binod Modi · InCred Wealth

partial

What is helping hold gross margin at 59% despite revenue decline?

It is a combination of multiple things. There is a positive, favorable mix in terms of the businesses... plus the existing product profile also good in the solid oral.